ICAD - Icad Inc Stock Price, Fair Value and News

$1.83+0.06 (+3.39%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ICAD Price Action

Last 7 days

-6.1%

Last 30 days

18.1%

Last 90 days

15.8%

Trailing 12 Months

9.6%

ICAD RSI Chart

ICAD Valuation

Market Cap

48.6M

Price/Earnings (Trailing)

-17.94

Price/Sales (Trailing)

2.56

EV/EBITDA

-5.93

Price/Free Cashflow

-10.42

ICAD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ICAD Fundamentals

ICAD Revenue

Revenue (TTM)

18.9M

Rev. Growth (Yr)

3.54%

Rev. Growth (Qtr)

-16.15%

ICAD Earnings

Earnings (TTM)

-2.7M

Earnings Growth (Yr)

-31.08%

Earnings Growth (Qtr)

-3.57%

ICAD Profitability

EBT Margin

-27.87%

Return on Equity

-9.22%

Return on Assets

-7.3%

Free Cashflow Yield

-9.6%

ICAD Investor Care

Shares Dilution (1Y)

0.71%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	17.9M	18.8M	18.9M	0
2023	18.8M	15.4M	15.1M	17.3M
2022	32.5M	32.3M	27.3M	21.9M
2021	31.8M	34.0M	36.3M	33.6M
2020	31.1M	29.4M	28.6M	29.7M
2019	26.1M	27.2M	28.9M	31.3M
2018	27.6M	27.4M	26.6M	25.6M
2017	27.1M	26.1M	27.1M	28.1M
2016	34.4M	30.6M	27.0M	26.3M
2015	48.6M	50.1M	47.1M	41.6M
2014	33.7M	35.6M	39.9M	43.9M
2013	29.9M	31.6M	31.8M	33.1M
2012	27.7M	26.9M	27.1M	28.3M
2011	25.4M	25.9M	28.4M	28.7M
2010	0	26.9M	25.8M	24.6M
2009	0	0	0	28.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Icad Inc

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

CEO	Ms. Dana R. Brown
WEBSITE	icadmed.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	108

Icad Inc Frequently Asked Questions

What is the ticker symbol for Icad Inc? What does ICAD stand for in stocks?

ICAD is the stock ticker symbol of Icad Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Icad Inc (ICAD)?

As of Fri Dec 20 2024, market cap of Icad Inc is 48.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICAD stock?

You can check ICAD's fair value in chart for subscribers.

Is Icad Inc a good stock to buy?

The fair value guage provides a quick view whether ICAD is over valued or under valued. Whether Icad Inc is cheap or expensive depends on the assumptions which impact Icad Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICAD.

What is Icad Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ICAD's PE ratio (Price to Earnings) is -17.94 and Price to Sales (PS) ratio is 2.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICAD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Icad Inc's stock?

In the past 10 years, Icad Inc has provided -0.152 (multiply by 100 for percentage) rate of return.